ONCLADEG
Live / Allowed — Approved for publication (as of 02 Apr 2026)
What this means for you
Approved and waiting on proof of use. It will register unless the applicant drops it, and its 02 Mar 2026 filing date already counts against anyone who files later.
Record
- Serial number
- 99679088
- Mark type
- Stylized text
- Filed
- 02 Mar 2026
- Attorney of record
- Kristen S. Ruisi
Goods and services
- Class 005 — Pharmaceuticals: Medicines for human purposes for the treatment of cancer, autoimmune and inflammatory diseases, rheumatoid arthritis, cardiovascular diseases and infectious diseases; pharmaceutical preparations for the treatment and prevention of cancer, autoimmune and inflammatory diseases, rheumatoid arthritis, cardiovascular diseases and infectious diseases; chemicopharmaceutical preparations for the treatment and prevention of cancer, autoimmune and inflammatory diseases, rheumatoid arthritis, cardiovascular diseases and infectious diseases; drugs for medical use being medicines for the treatment of cancer, autoimmune and inflammatory diseases, rheumatoid arthritis, cardiovascular diseases and infectious diseases; biological preparations for medical use for the treatment and prevention of cancer, autoimmune and inflammatory diseases, rheumatoid arthritis, cardiovascular diseases and infectious diseases; chemical preparations for pharmaceutical use, namely, for the treatment and prevention of cancer, autoimmune and inflammatory diseases, rheumatoid arthritis, cardiovascular diseases and infectious diseases; chemical preparations for medical use, namely, for the treatment and prevention of cancer, autoimmune and inflammatory diseases, rheumatoid arthritis, cardiovascular diseases and infectious diseases; injectable pharmaceuticals for treatment of cancer, autoimmune and inflammatory diseases, rheumatoid arthritis, cardiovascular diseases and infectious diseases; crude medicines for the treatment and prevention of cancer, autoimmune and inflammatory diseases, rheumatoid arthritis, cardiovascular diseases and infectious diseases; biochemical preparations for medical use, namely, the treatment and prevention of cancer, autoimmune and inflammatory diseases, rheumatoid arthritis, cardiovascular diseases and infectious diseases
Owner
- BeOne Medicines I GmbH, Basel, CH
Prosecution history
- 02 Apr 2026 — APPROVED FOR PUB - PRINCIPAL REGISTER
- 01 Apr 2026 — TEAS/EMAIL CORRESPONDENCE ENTERED
- 01 Apr 2026 — CORRESPONDENCE RECEIVED IN LAW OFFICE
- 01 Apr 2026 — TEAS RESPONSE TO OFFICE ACTION RECEIVED
- 20 Mar 2026 — NOTIFICATION OF NON-FINAL ACTION E-MAILED
- 20 Mar 2026 — NON-FINAL ACTION E-MAILED
- 20 Mar 2026 — NON-FINAL ACTION WRITTEN
- 19 Mar 2026 — ASSIGNED TO EXAMINER
- 02 Mar 2026 — APPLICATION FILING RECEIPT MAILED
- 02 Mar 2026 — NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
- 02 Mar 2026 — NEW APPLICATION ENTERED